Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

Invited panelists are:

• Robert Darnell, M.D., Ph.D, Investigator, Howard Hughes Medical Institute Heilbrunn Cancer Professor and Senior Physician, The Rockefeller University
• Neil K. Warma, President & Chief Executive Officer of Opexa Therapeutics, Inc.
• Dawn McGuire, M.D., Chair Clinical Advisory Board, Opexa Therapeutics, Inc.

The event will be moderated by Elemer Piros, Ph.D, Senior Biotechnology Analyst at Rodman & Renshaw, LLC.

The presentation will take place at the Rodman & Renshaw Offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020) at 4:30PM ET on April 7, 2010.